Coverage
-
October 27, 2016
Novartis Pharmaceuticals Corp. and Amneal Pharmaceuticals Inc. have settled a suit accusing generic drugmaker Amneal of infringing two patents when applying to sell its own version of the dementia-treatment patch, Exelon, according to an order signed Wednesday in Delaware federal court.
1 other articles on this case.
View all »